Jiangsu Recbio Technology Co., Ltd. released its fifth ESG report, detailing 2025 milestones across governance, climate action, product innovation and workforce development.
Governance and Risk • The “Two Committees, One Management” structure was maintained, with 12 board members—seven holding doctoral degrees and one female director. Non-executives account for two-thirds of the board. • A three-line risk-control model now covers routine monitoring, legal review and internal audit, producing 30 audit findings, 19 already rectified. • Anti-corruption policies were reinforced; no litigation or whistle-blower retaliation cases were recorded.
Climate Strategy and Environmental Metrics • Scope 1+2 greenhouse-gas emissions reached 26,236.89 tCO₂e, up from 19,517.43 tCO₂e in 2024, mainly due to higher purchased-power usage. • First-time disclosure of Scope 3 emissions: 426.74 tCO₂e from business travel and employee commuting. • 413.22 kW rooftop photovoltaic system went online, forecast to generate 0.46 million kWh in the first year and 10.48 million kWh over 25 years. • Targets set: by 2030, 8 % reduction in GHG-emission intensity, 5 % cut in hazardous-waste intensity and 8 % drop in energy-consumption intensity (baseline 2021).
Product Quality and Innovation • The shingles vaccine REC610 completed Phase III enrolment; the NDA has been accepted by the National Medical Products Administration. • Nine-valent HPV vaccine REC603 advanced through Phase III in China while overseas market preparations began. • Six novel adjuvants—including BFA01 and BFA03—were added to CEPI’s adjuvant library.
Talent and Diversity • Year-end headcount stood at 498, with female employees representing 46 %. Master’s degree holders and above accounted for 20.28 %. • A broadband pay system and quarterly “honour & gratitude” instant-recognition programme issued 1,627 reward cards since 2023. • Internal learning platform uploaded 1,000+ videos and 103 new courses, generating 4,000+ training hours.
Health, Safety and Ethics • Zero work-related fatalities; six lost workdays due to injuries. • Comprehensive animal-welfare oversight introduced; company passed all internal and external compliance audits. • No data-privacy or cybersecurity breaches occurred; a new encryption system and APT early-warning platform were deployed.
Community and Inclusive Healthcare • Continued procurement-linked rural-revitalisation initiative purchased local agricultural products for employee welfare, committing RMB 300,000 to community programmes. • Participated in national forums to promote vaccine accessibility and advocated fair-pricing mechanisms aligned with patient affordability.
Outlook Recbio states it will expand its photovoltaic capacity, integrate ESG metrics into remuneration and deepen collaboration with academic partners to sustain innovation and climate-aligned growth.
Comments